Pump Prime Aprotinin Fails to Limit Proinflammatory Cytokine Release After Coronary Artery Bypass Surgery
- 1 January 2001
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Cardiovascular Journal
- Vol. 35 (1) , 50-54
- https://doi.org/10.1080/140174301750101528
Abstract
Background - The purpose of this study was to establish whether pump prime aprotinin could limit the cytokine responses in patients undergoing elective coronary artery bypass surgery. Methods - Twenty-one patients admitted for first-time elective coronary artery bypass surgery were randomized into control or aprotinin groups. Patients in the aprotinin group received 280 mg aprotinin in the pump prime. Leukocyte count, creatine kinase cardiac isoenzyme (CK-MB), cytokine production and postoperative blood loss were analyzed perioperatively and compared with preoperative values. ResultsKeywords
This publication has 7 references indexed in Scilit:
- “Low-Dose” Aprotinin Modifies Hemostasis but Not Proinflammatory Cytokine ReleaseThe Annals of Thoracic Surgery, 1997
- Aprotinin for Primary Coronary Artery Bypass Grafting: A Multicenter Trial of Three Dose RegimensThe Annals of Thoracic Surgery, 1996
- Measurement of Cytokine Levels by Coronary Sinus Blood Sampling During Cardiac Surgery With Cardiopulmonary BypassPublished by Wolters Kluwer Health ,1996
- Heparin bonding of bypass circuits reduces cytokine release during cardiopulmonary bypassThe Annals of Thoracic Surgery, 1995
- Interleukin-8 gene induction in the myocardium after ischemia and reperfusion in vivo.Journal of Clinical Investigation, 1995
- Aprotinin in perspectiveThe Annals of Thoracic Surgery, 1993
- Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypassThe Annals of Thoracic Surgery, 1992